Amy K. Erbe

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

This paper describes a bispecific antibody that targets GD2 and B7-H3 to improve tumor targeting and reduce toxicity in neuroblastoma treatment.

This study identifies treatment-induced neutrophil states in tumors using single-cell multi-omics, showing ICAM1 as a marker of anti-tumor activity and potential biomarker for immunotherapy response.

This study compares the immune effects of alpha- and beta-particle emitting radiopharmaceuticals combined with immune checkpoint inhibitors in murine tumor models, finding distinct mechanisms of action based on radiation type.

The paper shows CD4 T regulatory cells can kill tumor cells through trogocytosis after immunocytokine treatment in a melanoma model.

This paper optimizes CRISPR/Cas9 AAV transduction for generating murine CAR-T cells with high efficiency and minimal toxicity, enabling in vivo persistence and pre-clinical testing.

This study examines how CD8 T cells with different metabolic profiles contribute to tumor cure in hot versus cold murine tumors using radio-immunotherapy.

This paper develops a bispecific antibody targeting GD2 and B7-H3 to improve tumor selectivity and reduce toxicity in GD2-positive tumors.

The paper introduces HERON, an R package for identifying immunogenic epitopes from ultradense peptide binding arrays across multiple samples.